BioPharma agrees USD500m loan deal with TESARO

Biopharma

BioPharma Credit has confirmed that it and BioPharma Credit Investments IV entered into a definitive loan agreement for up to USD500m with TESARO, Inc.

Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors said: “We are pleased to partner with TESARO in this transaction.

“We believe that TESARO is well on its way to becoming an oncology leader with an excellent management team, portfolio of commercial products with blockbuster potential in their current indications, and an exciting clinical development program that will one day offer patients additional indications for niraparib as well as new immuno-oncology therapies.”